OraSure Technologies (OSUR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
15 Jan, 2026Executive summary
Altai Capital nominated two candidates, including its founder, for election to the board at the 2026 annual meeting; the board will review these nominations and provide recommendations in the definitive proxy statement.
The board has undergone significant refreshment since 2022, with seven directors departing and three new independent directors added, including a new chair appointed in October 2025.
Shareholders are not required to take any action at this time; the annual meeting date has not yet been scheduled.
Forward-looking statements caution that actual results may differ due to various risk factors disclosed in SEC filings.
Voting matters and shareholder proposals
Altai Capital's nominations will be reviewed by the Nominating and Corporate Governance Committee, with recommendations to be included in the upcoming proxy statement.
Shareholders will receive the proxy statement and voting instructions when available; no immediate action is required.
Board of directors and corporate governance
The board is described as strong, independent, and engaged, with recent additions bringing industry and executive experience.
John P. Kenny was appointed as board chair in October 2025.
The board has engaged with Altai Capital but ultimately appointed an alternative candidate after interviewing Altai's nominee.
Latest events from OraSure Technologies
- Transformation strategy and board refresh set stage for growth amid proxy contest with Altai Capital.OSUR
Proxy Filing17 Mar 2026 - Q4 2025 revenue was $26.8 million, with margin gains and new product launches expected in 2026.OSUR
Q4 202525 Feb 2026 - Q2 revenue was $54.3M, with improved margins and new products supporting future growth.OSUR
Q2 20242 Feb 2026 - Q3 revenue fell 55% YoY; focus shifts to diagnostics, HCV self-test, and new growth markets.OSUR
Q3 202416 Jan 2026 - Streamlined operations and strong cash flow set the stage for growth in diagnostics and precision health.OSUR
Stephens 26th Annual Investment Conference13 Jan 2026 - Acquisition boosts rapid molecular self-testing, targeting STI markets and growth from 2026.OSUR
M&A Announcement10 Jan 2026 - Innovation, new launches, and financial strength drive growth and margin expansion in 2025.OSUR
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Core revenue up 10% YoY, COVID-19 sales down, innovation and margin growth prioritized.OSUR
Q4 202424 Dec 2025 - Board refreshment, director nominations, and a $40M buyback highlight this proxy update.OSUR
Proxy Filing17 Dec 2025